CLINICAL_TRIALS ClinicalTrials.gov record update

BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00570700
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:23.292364+00:00
Published At: 2018-05-25T00:00:00+00:00
Record Updated At: 2019-02-26
Results Posted At: 2018-05-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hormone-refractory Prostate Cancer", "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Prostate Cancer", "Recurrent Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-02-26"
protocolSection.identificationModule.nctId: "NCT00570700"
protocolSection.identificationModule.officialTitle: "BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel\u00ae) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-05-25"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.